3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
2
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Breast
1
Conditions
Prostatic Neoplasms
2
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
AZD5305
×
Genitourinary
×
Clear all
NCT06120491
2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3
Active not recruiting
1,889 enrolled
NCT06952803
2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3
Recruiting
700 enrolled